Sang­amo/Pfiz­er are catch­ing up to Bio­Marin and Spark with a gene ther­a­py for he­mo­phil­ia A — can they leapfrog ahead?

Sang­amo re­searchers and their part­ners at Pfiz­er may be play­ing catch-up with Bio­Marin and Spark/Roche in de­vel­op­ing a gene ther­a­py to cure he­mo­phil­ia A, but they’re off to an en­cour­ag­ing start.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER